Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent reform markup

Executive Summary

A markup of sweeping legislation to update the U.S. patent system for the first time in 50 years remains on the Senate Judiciary Committee's agenda for June 21 after being held over last week to allow further deliberation. A letter from several Republican committee members to Committee Chair Patrick Leahy, D-Vt., and Ranking Member Arlen Specter, R-Penn., says additional discussion among members, staff, the Patent and Trademark Office, the Department of Justice, and stakeholders is needed. The bill has moved rapidly through both houses of Congress, with contentious provisions including mandatory apportionment of damages, post-grant opposition, the granting of broad rule-making authority to PTO, and possible amendment of the Inequitable Conduct Doctrine (1"The Pink Sheet," June 11, 2007, p. 8)...

You may also be interested in...

PTO Wants Inequitable Conduct Doctrine Revised in Patent Reform Bill

With identical patent reform legislation moving rapidly through both houses of Congress, the U.S. Patent and Trademark Office is asking that the inequitable conduct doctrine be revised to encourage applicants to provide more and better information to examiners about their inventions

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts